Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,826 across all filing types
Latest filing 2021-07-16 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司关于收到征收补偿款的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of compensation payments related to property expropriation. It details the amounts received, the agreement with the local government, and the expected impact on the company's financials. The document is short (802 characters) and serves as a formal notification to shareholders and the market about a specific financial event, not a full financial report or detailed analysis. It does not contain comprehensive financial statements or detailed management discussion. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2021-07-16 Chinese
哈药集团股份有限公司独立董事独立董事关于公司对外投资暨关联交易事项的独立意见
Board/Management Information Classification · 90% confidence The document is an independent director's opinion on the company's external investment and related party transaction matters. It references compliance with regulatory rules and company bylaws, and discusses the fairness and legality of the transaction. It does not contain financial statements or detailed financial data, nor is it a report or announcement of financial results. It is a governance-related document focused on board oversight and compliance with regulations regarding related party transactions. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board or management decisions and opinions.
2021-06-27 Chinese
哈药集团股份有限公司关于对上海证券交易所《关于对哈药集团股份有限公司有关对外投资暨关联交易进展事项的问询函》的回复公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Harbin Pharmaceutical Group Co., Ltd. (哈药股份) responding to an inquiry from the Shanghai Stock Exchange regarding the company's external investments and related party transactions, specifically focusing on a 2018 agreement involving investment in GNC Holdings Inc. and the establishment of joint ventures in Hong Kong and Shanghai. The text includes extensive legal and financial explanations about the status of agreements, obligations, potential breaches, and financial data related to the joint ventures and investments. It discusses contract terms, compliance, financial performance, and operational details of the joint ventures. The document is lengthy (15,000 characters) and contains substantive financial and operational data, legal analysis, and management responses. It is not a brief announcement or a simple notification but a comprehensive disclosure and explanation of ongoing investment and related party transaction matters. This type of document fits best under Regulatory Filings (RNS) because it is a regulatory response to an inquiry, providing detailed compliance and operational information, but it is not a formal annual or interim financial report, audit report, earnings release, or other specific report types. It is also not a report publication announcement since it contains the full content rather than just announcing a report's release. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-06-27 Chinese
哈药集团股份有限公司九届十一次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Harbin Pharmaceutical Group Co., Ltd. It details decisions made by the company's board regarding adjustments to investment obligations and financing plans related to a joint venture and strategic investor introduction. The text includes voting results, mentions of related party transactions, and references to compliance with company law and articles of association. There are no financial statements, quarterly or annual results, or audit information presented. The document is an official announcement of board decisions and related corporate governance matters, not a full report or financial disclosure. Therefore, it fits best under Board/Management Information (MANG). The document length is short (1839 characters), and it is not merely announcing a report publication but providing substantive board decision content.
2021-06-27 Chinese
哈药集团股份有限公司独立董事关于公司对外投资暨关联交易事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding a company's external investment and related party transaction. It references compliance with stock exchange listing rules and company bylaws, and it expresses approval for submitting the matter to the board. There is no indication of a full financial report, audit report, or earnings release. The content is related to board/management oversight and approval of corporate actions, specifically related to governance and management decisions. Therefore, it fits best under Board/Management Information (MANG). The document length is short and does not contain financial statements or detailed financial data, so it is not an Annual Report or Interim Report. It is not a regulatory filing or announcement of voting results. Hence, the classification is MANG with high confidence.
2021-06-27 Chinese
哈药集团股份有限公司关于对外投资暨关联交易进展情况的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Harbin Pharmaceutical Group Co., Ltd. regarding an external investment and related party transaction progress. It includes specifics about the investment amount, agreements, board approvals, risks, financial data of the investee company, and the impact on the listed company. The document is not a full financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is a regulatory announcement about a significant investment transaction and related party dealings, which does not fit into categories like M&A filings or capital changes but is a regulatory disclosure about corporate transactions. Therefore, it best fits the category of Regulatory Filings (RNS). The document length is 4575 characters, which is substantial but not a full financial report. Hence, the classification is RNS with high confidence.
2021-06-27 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.